Rheumatoid factor IgM autoantibodies control IgG homeostasis.
affinity
autoantibodies
autoimmunity
homeostasis
rheumatoid factor
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
10
08
2022
accepted:
05
10
2022
entrez:
7
11
2022
pubmed:
8
11
2022
medline:
9
11
2022
Statut:
epublish
Résumé
Rheumatoid arthritis is an autoimmune disease characterized by joint inflammation due to autoantibodies targeting multiple self-proteins. Most patients with poor prognosis show elevated titers of IgM antibodies specifically binding to IgG. Such autoreactive antibodies are referred to as rheumatoid factor (RF). However, their biological function and contribution to disease progression remains elusive. We have recently shown that autoreactive antibodies are present in healthy individuals and play an important role in regulating physiological processes. This regulatory mechanism is determined by the class and affinity of the autoreactive antibody, as low-affinity autoreactive IgM neutralizes the recognized autoantigen while high-affinity IgM protects its autoantigen from degradation. Here, we show that RFs possessing a high affinity and mono-specificity to IgG have a stabilizing effect on IgG, whereas low-affinity polyreactive RFs neutralize IgG
Identifiants
pubmed: 36341420
doi: 10.3389/fimmu.2022.1016263
pmc: PMC9634112
doi:
Substances chimiques
Rheumatoid Factor
9009-79-4
Autoantibodies
0
Immunoglobulin M
0
Autoantigens
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1016263Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2022 Nicolò, Amendt, El Ayoubi, Young, Finzel, Senel, Voll and Jumaa.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Mol Immunol. 1991 Oct;28(10):1073-83
pubmed: 1681428
Immunity. 2003 Nov;19(5):679-88
pubmed: 14614855
Science. 2003 Sep 5;301(5638):1374-7
pubmed: 12920303
J Exp Med. 1986 Aug 1;164(2):407-27
pubmed: 3088205
EMBO J. 2021 Sep 1;40(17):e107621
pubmed: 34369608
Cytokine Growth Factor Rev. 2011 Oct-Dec;22(5-6):339-44
pubmed: 22119010
Front Immunol. 2022 Aug 01;13:972121
pubmed: 35979360
Nat Clin Pract Rheumatol. 2007 Feb;3(2):86-95
pubmed: 17299446
J Immunol. 1992 May 15;148(10):3296-301
pubmed: 1578151
J Clin Invest. 1994 Feb;93(2):852-61
pubmed: 7509350
Eur J Immunol. 1997 Mar;27(3):735-41
pubmed: 9079816
Semin Arthritis Rheum. 1988 Aug;18(1):61-71
pubmed: 3055304
Nature. 1988 Aug 25;334(6184):676-82
pubmed: 3261841
Nat Rev Immunol. 2017 Jan;17(1):60-75
pubmed: 27916980
J Exp Med. 1993 Jan 1;177(1):109-18
pubmed: 8418195
Arthritis Rheumatol. 2022 Aug;74(8):1305-1317
pubmed: 35289109
Antibodies (Basel). 2021 Feb 25;10(1):
pubmed: 33668697
J Clin Invest. 2015 Jun;125(6):2194-202
pubmed: 25938780
Immunol Rev. 2020 Mar;294(1):148-163
pubmed: 31845355
J Exp Med. 2005 Mar 7;201(5):703-11
pubmed: 15738055
Ann N Y Acad Sci. 1995 Sep 29;764:440-9
pubmed: 7486562
Trends Immunol. 2009 Jan;30(1):43-51
pubmed: 19058756
Curr Opin Immunol. 1995 Dec;7(6):812-8
pubmed: 8679125
Sci Rep. 2018 Jun 20;8(1):9392
pubmed: 29925848
J Allergy Clin Immunol. 2013 Apr;131(4):959-71
pubmed: 23465663
Proc Natl Acad Sci U S A. 1989 Oct;86(20):8039-43
pubmed: 2682636
Arthritis Rheum. 1968 Feb;11(1):50-5
pubmed: 5640610
Curr Opin Rheumatol. 2018 Jan;30(1):72-78
pubmed: 28937414
Arthritis Rheum. 2012 Oct;64(10):3388-98
pubmed: 22577035
Atherosclerosis. 2013 May;228(1):243-6
pubmed: 23474125
Mol Immunol. 2000 Dec;37(18):1141-9
pubmed: 11451419
Nature. 1989 Feb 9;337(6207):562-6
pubmed: 2783762
J Exp Med. 1993 Apr 1;177(4):1009-20
pubmed: 8459201
J Exp Med. 1991 Feb 1;173(2):487-9
pubmed: 1703209
J Immunol. 1994 Feb 1;152(3):1430-41
pubmed: 8301143
J Immunol. 2015 Dec 1;195(11):5309-17
pubmed: 26500348
Bioessays. 2022 Mar;44(3):e2100236
pubmed: 34984705
Front Immunol. 2018 Mar 29;9:623
pubmed: 29651292
Nat Rev Dis Primers. 2018 Feb 08;4:18001
pubmed: 29417936
Front Oncol. 2018 Jun 04;8:163
pubmed: 29915719
Mol Med. 2003 May-Aug;9(5-8):166-74
pubmed: 14571324
Microbiol Spectr. 2014 Dec;2(6):
pubmed: 26104458
Ann N Y Acad Sci. 1997 Apr 5;815:361-3
pubmed: 9186679
J Exp Med. 1983 Aug 1;158(2):529-45
pubmed: 6350525
Clin Exp Immunol. 1983 Feb;51(2):299-304
pubmed: 6601551
Ann N Y Acad Sci. 1997 Apr 5;815:296-311
pubmed: 9186666
Semin Arthritis Rheum. 2019 Feb;48(4):603-610
pubmed: 30032973
PLoS One. 2011 Mar 23;6(3):e17223
pubmed: 21448268
Scand J Immunol. 1997 Apr;45(4):393-400
pubmed: 9105427
Cell Mol Immunol. 2020 Jun;17(6):561-569
pubmed: 32382130
Inflamm Regen. 2020 Sep 7;40:20
pubmed: 32944095
Immunity. 2003 Jul;19(1):21-31
pubmed: 12871636
Autoimmunity. 2005 Jun;38(4):259-64
pubmed: 16206508
JAMA. 2018 Oct 02;320(13):1360-1372
pubmed: 30285183
Proc Natl Acad Sci U S A. 2000 Feb 1;97(3):1184-9
pubmed: 10655505
Curr Opin Drug Discov Devel. 2009 Sep;12(5):616-27
pubmed: 19736621
J Clin Invest. 2015 Jun;125(6):2203-10
pubmed: 25938781
Cell Rep. 2019 Jul 23;28(4):923-937.e3
pubmed: 31340154
J Exp Med. 2005 May 16;201(10):1659-67
pubmed: 15897279
Front Med (Lausanne). 2018 Dec 03;5:339
pubmed: 30560132
Nature. 2012 Sep 6;489(7414):160-4
pubmed: 22902503
Cancer Chemother Pharmacol. 2001 Aug;48 Suppl 1:S85-90
pubmed: 11587374
Proc Natl Acad Sci U S A. 2022 Feb 8;119(6):
pubmed: 35131852
Methods Mol Biol. 2015;1278:165-82
pubmed: 25859949
Arthritis Res Ther. 2012;14 Suppl 4:S1
pubmed: 23281837
J Exp Med. 1987 Apr 1;165(4):970-87
pubmed: 3494096
J Exp Med. 1993 Apr 1;177(4):999-1008
pubmed: 8459227